A flow chart of the linkage to care pathway and outcomes for hepatitis C antigen patients (n = 32).

<p>^a Includes two patients actively not contacted. ^b Includes one re-infected patient and one not contacted but identified on EPR. ^c Not contacted but identified on EPR. ^d Attended one clinic appointment. ^e Attended ≥1 clinic appointments.</p

Demographics of ED attendees, blood tested patients and those tested for viral hepatitis, GSTFT, 15 February-28 March 2016.

<p>Demographics of ED attendees, blood tested patients and those tested for viral hepatitis, GSTFT, 15 February-28 March 2016.</p

Genetic sequence similarities between ZIKV strains using the study.

<p>Genetic sequence similarities between ZIKV strains using the study.</p

Prevalence and risk factors for hepatitis C virus infection, GSTFT, 15 February–28 March 2016.

<p>Prevalence and risk factors for hepatitis C virus infection, GSTFT, 15 February–28 March 2016.</p

A flow chart of the linkage to care pathway and outcomes for positive hepatitis B surface antigen patients (n = 26).

<p>^a Includes two not contacted but identified on EPR. ^b Attended one clinic appointment. ^c Attended ≥1 clinic appointments.</p

Histological findings in spleen, liver, testis and heart of A129 mice infected with ZIKV.

<p>Histological findings in spleen, liver, testis and heart of A129 mice infected with ZIKV.</p

Clinical data and viral burden from A129 mice challenged with ZIKV^AF and ZIKV^AS.

<p>6–8 week old A129 mice were subcutaneously challenged with a high (10⁶ pfu) or low (10 pfu) dose of ZIKV^AF or ZIKV^AS. At days 1, 3, 5 and 7 post-challenge, a cohort of mice from each group were culled for assessment of local response. (A) Kaplin-Meier survival plot. (B) Differences in weight compared to day of challenge. (C) Differences in temperatures compared to day of challenge. (D) Clinical score, with numerical values given as follows: 0, normal; 2, ruffled fur; 3, lethargy, pinched, hunched, wasp waisted; 5, laboured breathing, rapid breathing, inactive, neurological; and 10, immobile. (E) Viral burden in local tissues (spleen, liver, brain, kidney, lung, testes, heart and blood) at days 1, 3, 5, 7 and 14 post-challenge. (F) Viral burden in secretions (saliva and rectal swabs) of animals at days 1, 3, 5, 7 and 14 post-challenge. Graphs A-D: group sizes were n = 6.Graphs B—D show the mean values with error bars denoting standard error. Graphs E-F: groups sizes of n = 3, with bar denoting mean values and error bars denoting standard error. Abbreviations: <, below the limit of detection; x, no results as animals had previously met humane endpoints; and *, statistical significance (P = 0.0809, Mann-Whitney test).</p

Viral RNA staining in tissues from A129 mice challenged with ZIKV.

<p>Viral RNA staining in tissues from A129 mice challenged with ZIKV.</p

Histological and RNA <i>in situ</i> hybridisation findings in the spleen, testes and heart of ZIKV-challenge A129 mice.

<p>(A) Spleen. Poorly defined areas comprising large mononuclear cells within the white pulp (Animal 86783, 10⁶ pfu ZIKV^AF, day 5). Inset, normal spleen with well defined, small germinal centres within the white pulp (Animal 86739, unchallenged). (B) Spleen. Prominent, extra-medullary haematopoiesis in the red pulp. Rectangle, numerous PMNs in the red pulp sinuses (Animal 86724, 10⁶ pfu ZIKV^AF, day 7). (C) Testis. Expansion of the interstitial tissue by proteinaceous fluid, macrophages and PMNs. Inset, higher power image of area within white square (Animal 86772, 10 pfu ZIKV^AF, day 5). (D) Testis. Mild infiltration of PMNs into the interstitial space with positive viral staining (Animal 86779, 10⁶ ZIKV^AF, day 3). (E) Testis. Positive staining of virally infected cells focally within the walls of the seminiferous tubules (white arrows) as well as within the interstitium (Animal 86784, 10 pfu ZIKV^AF, day 7). (F) Testis. Epididymis with positive staining of cells in lumen and epithelium of the efferent ductules as well as the interstitium (Animal 86784, 10 pfu ZIKV^AF, day 7). (G) Testis. Positive staining of cells in the necrotic seminiferous tubules (Animal 86744, 10⁶ pfu ZIKV^AS, day 14). (H) Testis. Intra-tubular and interstitial cell staining (Animal 86757, 10⁶ pfu ZIKV^AS, day 7). (I) Heart. Infiltration of myocardium by macrophages and PMNs (Animal 86779, 10⁶ ZIKV^AF, day 3). (J) Heart. Infiltration of an atrio-ventricular valve by macrophages and PMNs (Animal 86780, 10⁶ pfu ZIKV^AF, day 3). A-C and I-J show sections stained with haematoxylin and eosin (H&E) and D-H show RNA <i>in situ</i> hybridisation images.</p

Clinical data from A129 mice challenged with different strains of ZIKV^AS.

<p>5–8 week old A129 mice were subcutaneously challenged with 10⁶ pfu ZIKV^AS virus. (A) Kaplin-Meier survival plot. (B) Differences in weight compared to date of challenge. (C) Temperature change compared to date of challenge. Graphs B and C show the mean values with error bars denoting standard error. Group sizes were n = 5.</p